Artivion, Inc. (NYSE: AORT) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 107.02 | EPS (ttm) | 0.25 | Insider Own | 6.75% | Shs Outstand | 48.54M | Perf Week | 6.13% |
| Market Cap | 1.30B | Forward P/E | 65.84 | EPS next Y | 0.41 | Insider Trans | -5.40% | Shs Float | 46.07M | Perf Month | 13.93% |
| Enterprise Value | 1.50B | PEG | 0.22 | EPS next Q | - | Inst Own | - | Short Float | 5.42% | Perf Quarter | -25.12% |
| Income | 11.85M | P/S | 2.84 | EPS this Y | -65.10% | Inst Trans | - | Short Ratio | 3.32 | Perf Half Y | -33.62% |
| Sales | 458.69M | P/B | 2.86 | EPS next Y | 386.57% | ROA | 1.32% | Short Interest | 2.50M | Perf YTD | -41.18% |
| Book/sh | - | P/C | 22.94 | EPS next 5Y | 108.08% | ROE | 2.66% | 52W High | 49.40 -44.39% | Perf Year | -15.01% |
| Cash/sh | - | P/FCF | 101.51 | EPS past 3/5Y | - | ROIC | 3.00% | 52W Low | 19.62 40.03% | Perf 3Y | 57.18% |
| Dividend Est. | - | EV/EBITDA | 23.13 | Sales past 3/5Y | 11.99% 11.75% | Gross Margin | 62.94% | Volatility | 3.46% 3.79% | Perf 5Y | 4.15% |
| Dividend TTM | - | EV/Sales | 3.28 | EPS Y/Y TTM | 175.00% | Oper. Margin | 7.76% | ATR (14) | 1.06 | Perf 10Y | 123.77% |
| Dividend Ex-Date | Dec 09, 2015 | Quick Ratio | 2.22 | Sales Y/Y TTM | 17.74% | Profit Margin | 2.55% | RSI (14) | 61.92 | Recom | 2.17 |
| Dividend Gr. 3/5Y | 33.89% - | Current Ratio | 3.28 | EPS Q/Q | -50.00% | SMA20 | 6.46% | Beta | 1.24 | Target Price | 40.50 |
| Payout | 0.00% | Debt/Eq | 0.57 | Sales Q/Q | 17.17% | SMA50 | 16.20% | Rel Volume | 0.76 | Prev Close | 26.83 |
| Employees | 1,800 | LT Debt/Eq | 0.64 | Earnings | Aug 06 | SMA200 | -25.23% | Avg Volume | 803.77K | Price | 27.47 |
| IPO Date | Feb 12, 1993 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 14.29% 0.56% | Net Debt/EBITDA | 3.11 | Volume | 614,645 | Change | 2.39% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-16-26 | Reiterated | Canaccord Genuity | Buy | $51 → $36 |
| Jun-01-26 | Reiterated | Stifel Nicolaus | $55 → $45 | |
| Apr-10-26 | Upgrade | Ladenburg Thalmann | Neutral → Buy | |
| Mar-05-26 | Reiterated | Stifel Nicolaus | $55 | |
| Dec-17-25 | Reiterated | Canaccord Genuity | Buy | $51 |
| Nov-07-25 | Reiterated | Oppenheimer | Outperform | $30 → $50 |
| Aug-13-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral | |
| Aug-08-25 | Reiterated | Needham | Buy | $30 → $45 |
| Oct-23-24 | Reiterated | JMP Securities | $33 | |
| Aug-09-24 | Reiterated | Oppenheimer | Outperform | $30 |
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 458 | 441 | 389 | 354 | 314 | 299 | 253 | 276 | 263 | |
| Cost of Goods Sold Incl. D&A | 170 | 171 | 140 | 125 | 111 | 101 | 85 | 93 | 90 | |
| Gross Profit | 289 | 270 | 249 | 229 | 203 | 198 | 168 | 183 | 173 | |
| Selling, General and Administrative Excl. Other | 221 | 213 | 192 | 209 | 157 | 170 | 141 | 143 | 141 | |
| Research and Development | 33 | 31 | 28 | 29 | 39 | 36 | 24 | 23 | 23 | |
| Other Operating Expense | -1 | 0 | -10 | -15 | 0 | -17 | 0 | 0 | 0 | |
| Operating Income | 35 | 27 | 39 | 6 | 6 | 8 | 2 | 17 | 9 | |
| Interest Expense | 24 | 27 | 34 | 25 | 18 | 17 | 17 | 15 | 16 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 6 | 15 | -12 | -2 | -3 | -6 | -3 | -1 | 0 | |
| Net Income Before Taxes | 17 | 15 | -8 | -22 | -15 | -15 | -17 | 2 | -6 | |
| Income Taxes | 6 | 5 | 6 | 9 | 4 | 0 | 0 | 0 | -3 | |
| Consolidated Net Income | 11 | 10 | -13 | -31 | -19 | -15 | -17 | 2 | -4 | |
| Net Income From Continuing Operations | 11 | 10 | -13 | -31 | -19 | -15 | -17 | 2 | -3 | |
| Net Income | 11 | 10 | -13 | -31 | -19 | -15 | -17 | 2 | -4 | |
| EPS (Recurring) | 0.25 | 0.22 | -0.32 | -0.75 | -0.48 | -0.38 | -0.44 | 0.05 | -0.11 | |
| EPS (Basic, Before Extraordinaries) | 0.25 | 0.22 | -0.32 | -0.75 | -0.48 | -0.38 | -0.44 | 0.05 | -0.11 | |
| EPS (Diluted) | 0.24 | 0.21 | -0.32 | -0.75 | -0.48 | -0.38 | -0.44 | 0.05 | -0.10 | |
| EBITDA | 65 | 64 | 51 | 27 | 26 | 26 | 20 | 35 | 30 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 114.46 | 217.19 | — | — | — | — | — | 600.67 | — | |
| Price To Sales Ratio | 2.88 | 4.65 | 3.09 | 2.07 | 1.54 | 2.65 | 3.55 | 3.63 | 3.78 | |
| Gross Margin | 63.10 | 61.22 | 64.01 | 64.69 | 64.65 | 66.22 | 66.40 | 66.30 | 65.78 | |
| Operating Margin | 7.64 | 6.12 | 10.03 | 1.69 | 1.91 | 2.68 | 0.79 | 6.16 | 3.42 | |
| Net Margin | 2.40 | 2.27 | -3.34 | -8.76 | -6.05 | -5.02 | -6.72 | 0.72 | -1.52 | |
| Shares Outstanding | 48 | 45 | 42 | 41 | 40 | 39 | 38 | 37 | 35 | |
| Market Capitalization | 1,319 | 2,052 | 1,201 | 733 | 485 | 794 | 897 | 1,002 | 993 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| GREEN ANDREW M | SVP, Regulatory and Quality | Jun 11 '26 | Sale | 20.70 | 44,001 | 910,739 | 60,259 | Jun 15 |
| GREEN ANDREW M | SVP, Regulatory and Quality | Jun 11 '26 | Option Exercise | 13.39 | 44,001 | 589,078 | 90,259 | Jun 15 |
| Holloway Jean F | SVP, General Counsel | Mar 04 '26 | Sale | 38.00 | 8,962 | 340,556 | 185,095 | Mar 04 |
| Horton Amy | VP, Chief Accounting Officer | Mar 03 '26 | Sale | 37.78 | 901 | 34,036 | 139,088 | Mar 04 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | Mar 03 '26 | Sale | 37.78 | 2,149 | 81,180 | 60,097 | Mar 04 |
| Holloway Jean F | SVP, General Counsel | Mar 03 '26 | Sale | 37.78 | 3,843 | 145,172 | 194,057 | Mar 04 |
| Berry Lance A | EVP, COO, CFO & Treasurer | Mar 03 '26 | Sale | 37.78 | 6,316 | 238,591 | 210,827 | Mar 04 |
| Mackin James P | President & CEO | Mar 03 '26 | Sale | 37.78 | 17,887 | 675,692 | 947,275 | Mar 04 |
| Davis John E | Chief Commercial Officer | Mar 03 '26 | Sale | 37.78 | 4,573 | 172,748 | 230,794 | Mar 04 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | Mar 02 '26 | Sale | 38.02 | 1,513 | 57,532 | 40,408 | Mar 03 |
| Horton Amy | VP, Chief Accounting Officer | Mar 02 '26 | Sale | 38.02 | 641 | 24,374 | 132,514 | Mar 03 |
| Berry Lance A | EVP, COO, CFO & Treasurer | Mar 02 '26 | Sale | 38.02 | 5,178 | 196,893 | 176,269 | Mar 03 |
| Mackin James P | President & CEO | Mar 02 '26 | Sale | 38.02 | 14,911 | 566,989 | 848,214 | Mar 03 |
| Holloway Jean F | SVP, General Counsel | Mar 02 '26 | Sale | 38.02 | 2,183 | 83,008 | 170,105 | Mar 03 |
| Davis John E | Chief Commercial Officer | Mar 02 '26 | Sale | 38.02 | 2,784 | 105,861 | 206,522 | Mar 03 |